Changes to Executive Board
After ten years at Evonik, Maike Schuh is leaving the company at her own request. ... MORE
After ten years at Evonik, Maike Schuh is leaving the company at her own request. ... MORE
Evonik’s Vecollan® recombinant, non-animal-derived collagen-like protein platform is now available in a grade suitable for use in clinical trials. ... MORE
Evonik, a global specialty chemicals company, and Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, have entered into a strategic collaboration to develop and market a novel lipid nanoparticle (LNP) platform for nucleic acid delivery. ... MORE
Evonik, a global specialty chemicals company, and Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, have entered into a strategic collaboration to develop and market a novel lipid nanoparticle (LNP) platform for nucleic acid delivery. ... MORE
Evonik is launching the Next Markets Program to drive additional growth. This initiative is designed to unlock markets that are closely linked to the company’s core businesses. ... MORE
Evonik is bundling its infrastructure activities of the Marl and Wesseling chemical parks in a joint unit. The new company is called SYNEQT GmbH and is scheduled to start operations on January 1, 2026. ... MORE